- Report
- September 2023
- 202 Pages
Global
From €4027EUR$4,450USD£3,440GBP
- Report
- September 2022
- 252 Pages
Global
From €4027EUR$4,450USD£3,440GBP
- Report
- January 2022
- 181 Pages
Global
From €4027EUR$4,450USD£3,440GBP
- Report
- June 2025
- 127 Pages
Global
From €2669EUR$2,950USD£2,280GBP
- Report
- December 2024
- 150 Pages
Global
From €2859EUR$3,160USD£2,443GBP
€3574EUR$3,950USD£3,053GBP
- Report
- December 2024
- 150 Pages
Global
From €2859EUR$3,160USD£2,443GBP
€3574EUR$3,950USD£3,053GBP
- Report
- December 2024
- 150 Pages
Global
From €2859EUR$3,160USD£2,443GBP
€3574EUR$3,950USD£3,053GBP
- Report
- July 2024
- 151 Pages
Global
From €3077EUR$3,400USD£2,628GBP
€3846EUR$4,250USD£3,285GBP
- Report
- March 2025
- 67 Pages
Global
From €1765EUR$1,950USD£1,507GBP
- Report
- January 2025
- 127 Pages
Global
From €2669EUR$2,950USD£2,280GBP
- Report
- May 2024
- 119 Pages
Global
From €1765EUR$1,950USD£1,507GBP
- Report
- December 2023
- 76 Pages
Global
From €7235EUR$7,995USD£6,180GBP
- Report
- December 2022
- 110 Pages
Global
From €1765EUR$1,950USD£1,507GBP
- Report
- May 2025
- 142 Pages
Global
From €3574EUR$3,950USD£3,053GBP
- Report
- April 2025
- 145 Pages
Global
From €3574EUR$3,950USD£3,053GBP
- Report
- December 2022
- 142 Pages
Global
From €4027EUR$4,450USD£3,440GBP
- Report
- December 2019
- 120 Pages
Global
From €3348EUR$3,700USD£2,860GBP
- Report
- June 2025
- 207 Pages
Global
From €4520EUR$4,995USD£3,861GBP
- Report
- May 2025
- 172 Pages
Europe
From €3167EUR$3,500USD£2,705GBP
- Report
- January 2025
- 146 Pages
Global
From €3574EUR$3,950USD£3,053GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more